Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory imide drug presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing, regulatory support and timely delivery across multiple continents. The product complies with EU quality standards and is manufactured under strict Good Manufacturing Practice guidelines, ensuring batch consistency and patient safety.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones.

Multiple Myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents. Myelodysplastic Syndromes: reduces transfusion dependence and may improve blood counts in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: contributes to disease control as part of combination therapy in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Fatigue - Nausea - Diarrhea - Neutropenia - Thrombocytopenia - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia or infections - Secondary primary malignancies - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic toxicity

When prescribing lenalidomide, clinicians should observe several safety measures.

Pregnancy testing: perform before initiation and monthly during therapy. Contraception: both male and female patients must use effective contraception. Blood monitoring: regularly assess complete blood counts and liver function. Thromboembolic risk: evaluate need for prophylactic anticoagulation. Infection risk: monitor for signs of infection and manage promptly. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomide interacts with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants: increased risk of bleeding. - Live vaccines: risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: may increase lenalidomide exposure. - Immunosuppressants: may augment infection risk. - Diuretics: may affect renal clearance.